# Hemophagocytic syndrome


Melissa Hovanetz, MD 04/17/06

### Case Study


9 y/o male with 2-week history of fevers, cough, dyspnea, vomiting

Lymphadenopathy, pancytopenia


Viral pneumonia-like picture




Peripheral blood




Bone marrow aspirate



Bone marrow aspirate





Bone marrow biopsy





Bone marrow biopsy

#### Lymph node biopsy









## Case Study - Diagnosis

Lymph node: Hemophagocytic lymphohistiocytosis, etiology undetermined

- Negative for CMV, EBV, Parvovirus
- Bone marrow: Extensive hemophagocytosis
  - No leukemia or lymphoma
- Viral-associated hemophagocytic syndrome (VAHS)
   HHV-6 serology = 3.56 (>1.11)
- Transferred to MDACC

## Syndrome Definition

- "Hemophagocytosis" Process by which macrophages engulf RBCs, WBCs, platelets and their precursors
- Hemophagocytic syndrome = Hemophagocytic lymphohistiocytosis (HLH)
  - Two main groups: Genetic and acquired
  - Highly active yet ineffective immune response that is life-threatening

### HLH – Clinical Criteria

- Cardinal sx: Fever, cytopenias, SM (LAD, skin rash, CNS)
- Laboratory findings
  - Elevated triglycerides, ferritin, transaminases, bilirubin, sCD25 (alpha chain of soluble IL-2 receptor)
  - Decreased fibrinogen
- Histopathology: Hemophagocytosis seen in spleen, BM, LN, CNS, skin, liver (but not always present)

Table 3. Diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH).\*

- 1. Familial disease/known genetic defect
- Clinical and laboratory criteria (5/8 criteria) Fever

Splenomegaly

- Cytopenia ≥ 2 cell lines Hemoglobin < 90 g/L (below 4 weeks < 120 g/L) Neutrophils < 1 ×10<sup>9</sup> /L
- Hypertriglyceridemia and/or hypofibrinogenemia fasting triglycerides ≥ 3 mmol/L fibrinogen < 1.5 g/L

Ferritin ≥ 500 µg/L

sCD25 ≥ 2400 U/mL §

Decreased or absent NK-cell activity

Hemophagocytosis in bone marrow, CSF or lymph nodes

Supportive evidence are cerebral symptoms with moderate pleocytosis and/or elevated protein, elevated transaminases and bilirubin, LDH > 1000 U/L

## HLH - Pathophysiology

Proliferation of activated macrophages/histiocytes that phagocytose RBCs, WBCs, platelets

Nonmalignant, but fatal without treatment

Not clonal

- Contrast with Langerhans cell histiocytosis

## HLH - Pathophysiology

- Theory: Inappropriate immune reaction caused by proliferating, active T cells and macrophages with inadequate apoptosis of immunogenic cells
- Impaired cytotoxic function of NK cells and CTLs
  - Decreased NK activity with persistent T-cell activation
- Cytokine hypersecretion, inflammatory response
  - IFN-gamma, TNF-alpha, IL-6, IL-10, M-CSF
  - Responsible for clinical signs, cytopenias, coagulopathy, high triglycerides
  - Infiltrate tissues and lead to necrosis and organ failure

Table 1. Classification and underlying conditions of hemophagocytic lymphohistiocytosis (HLH).

Genetic HLH

Familial HLH (Farquhar disease\*) Known gene defects (perforin, munc 13-4, syntaxin 11) Unknown gene defects

Immune deficiency syndromes Chédiak-Higashi syndrome (CHS) Griscelli syndrome (GS) X-linked lymphoproliferative syndrome (XLP)

Acquired HLH

Exogenous agents (infectious organisms, toxins) Infection-associated hemophagocytic syndrome (IAHS) Endogenous products (tissue damage, metabolic products) Rheumatic diseases Macrophage activation syndrome (MAS) Malignant diseases

\* Familial HLH was first described by Farquhar and Claireaux in 1952

Table 1. Classification and underlying conditions of hemophagocytic lymphohistiocytosis (HLH). Genetic HLH Familial HLH (Farquhar disease*) Known gene defects (perforin, munc 13-4, syntaxin 11) Unknown gene defects	<ul> <li>AR inheritance</li> <li>Present as young children</li> <li>Poor prognosis</li> </ul>
Immune deficiency syndromes Chédiak-Higashi syndrome (CHS) Griscelli syndrome (GS) X-linked lymphoproliferative syndrome (XLP)	
Acquired HLH	
Exogenous agents (infectious organisms, toxins) Infection-associated hemophagocytic syndrome (IAHS)	
Endogenous products (tissue damage, metabolic products)	
Rheumatic diseases Macrophage activation syndrome (MAS)	
Malignant diseases	
* Familial HLH was first described by Farquhar and Claireaux in 1952	

Table 1. Classification and underlying conditions of hemophagocytic lymphohistiocytosis (HLH).	
Genetic HLH Familial HLH (Farquhar disease*) Known gene defects (perforin, munc 13-4, syntaxin 11) Unknown gene defects	
Immune deficiency syndromes Chédiak-Higashi syndrome (CHS) Griscelli syndrome (GS) X-linked lymphoproliferative syndrome (XLP)	<ul><li>AR inheritance</li><li>Chronic pyogenic infections</li></ul>
Acquired HLH	
Exogenous agents (infectious organisms, toxins) Infection-associated hemophagocytic syndrome (IAHS)	Oculocutaneous albinism
Endogenous products (tissue damage, metabolic products)	
Rheumatic diseases Macrophage activation syndrome (MAS)	
Malignant diseases	
* Familial HLH was first described by Farquhar and Claireaux in 1952	

Table 1. Classification and underlying conditions of hemophagocytic lymphohistiocytosis (HLH).	
Genetic HLH Familial HLH (Farquhar disease*) Known gene defects (perforin, munc 13-4, syntaxin 11) Unknown gene defects	
Immune deficiency syndromes Chédiak-Higashi syndrome (CHS) Griscelli syndrome (GS) X-linked lymphoproliferative syndrome (XLP) Acquired HLH Exogenous agents (infectious organisms, toxins) Infection-associated hemophagocytic syndrome (IAHS) Endogenous products (tissue damage, metabolic products) Rheumatic diseases Macrophage activation syndrome (MAS) Malignant diseases	<ul> <li>Very rare</li> <li>AR inheritance</li> <li>Silver hair</li> </ul>
* Familial HLH was first described by Farquhar and Claireaux in 1952	

Table 1. Classification and underlying conditions of hemophagocytic lymphohistiocytosis (HLH).	
Genetic HLH Familial HLH (Farquhar disease*) Known gene defects (perforin, munc 13-4, syntaxin 11) Unknown gene defects	
Immune deficiency syndromes Chédiak-Higashi syndrome (CHS) Griscelli syndrome (GS) X-linked lymphoproliferative syndrome (XLP)	<ul> <li>Predilection for fatal EBV- induced mononucleosis</li> </ul>
Acquired HLH Exogenous agents (infectious organisms, toxins) Infection-associated hemophagocytic syndrome (IAHS) Endogenous products (tissue damage, metabolic products) Rheumatic diseases Macrophage activation syndrome (MAS)	<ul><li>Hypogammaglobulinemia</li><li>Risk for lymphoma</li></ul>
Malignant diseases	
* Familial HLH was first described by Farquhar and Claireaux in 1952	


#### Mechanisms of Genetic HLH:

#### Defective cytotoxic function

Table 2. Genetic defects in hemophagocytic NK cell and lymphohistiocytosis. Cytotoxic T cell Monocyte/ Chromosome Associated Macrophage/ Gene Function Disease Location Gene Dendritic cell FHLH-1 9a21.3-22 Not known Not known FHLH-2 10g21-22 PRF1 Induction of apoptosis Activation. FHLH-3 17g25 UNC13D Vesicle priming STX11 FHLH-4 6q24 Vesicle transport; LYST t-SNARE Polarization. RAB27A GS-2 15q21 Vesicle transport; small GTPase Docking. Rab27a 1q42.1-q42.2 LYST CHS-1 Vesicle transport; not Primino further defined Syntaxin 11 Xq25 SH2D1A XLP Signal transduction and Fusing activation of lympho-Munc13 cytes Abbreviations: FHLH, familial hemophagocytic lymphohistiocytosis; GS, Griscelli syndrome; CHS, Chédiak-Perforin Higashi syndrome; XLP, X-linked lymphoproliferative syndrome Killina Grone vines Target cell

Table 1. Classification and underlying conditions of hemophagocytic lymphohistiocytosis (HLH).	
Genetic HLH Familial HLH (Farquhar disease*) Known gene defects (perforin, munc 13-4, syntaxin 11) Unknown gene defects Immune deficiency syndromes Chédiak-Higashi syndrome (CHS) Griscelli syndrome (GS) X-linked lymphoproliferative syndrome (XLP)	
Acquired HLH Exogenous agents (infectious organisms, toxins) Infection-associated hemophagocytic syndrome (IAHS) Endogenous products (tissue damage, metabolic products) Rheumatic diseases Macrophage activation syndrome (MAS) Malignant diseases	<ul> <li>After strong immune activation</li> <li>Little incidence data</li> </ul>
* Familial HLH was first described by Farquhar and Claireaux in 1952	

#### Mechanisms of Infection-associated HLH



### HLH and Infection

 Viruses, bacteria, parasites, spirochetes, mycobacteria, fungi

Difficulty distinguishing acquired from familial
 – Familial cases may be precipitated by infection
 – May mimic an infectious illness

### HLH and Infection

- Impractical to exclude all possible infectious causes
- If HLH criteria are met, then screen for EBV, CMV, parvovirus B19, HIV
- History should guide testing
  - HIV infection: Pneumococcus, Pneumocystis,
     Histoplasma, *Penicillium marneffei*, T-cell lymphoma
  - Animal exposure: Brucella, Rickettsia
  - Travel exposure: Leishmania, malaria

#### HLH and other Associations

MalignancyT-cell lymphoma

- Autoimmune diseases
  - Macrophage activation syndrome
  - Juvenile RA, Still's disease, SLE

## HLH - Laboratory

- CBC, AST/ALT, bilirubin, TG, ferritin, coags (fibrinogen)
- Bone marrow: Insensitive
  - May be negative in 2/3 of initial aspirates
  - Dysplastic RBCs  $\rightarrow$  myelodysplasia
- sCD25 >2400 U/ml
  - Highly specific serum parameter
- NK cell perforin expression by flow cytometry
- Genetic testing
  - PRF1, Munc13-4 available at Cincinnati Children's Hospital

### HLH - Treatment

- Immediate goal: Immune suppression
  - Corticosteroids
  - Dexamethasone: Preferred, Xs BBB > prednisolone
  - Cyclosporin A: prevents T cell activation
  - Etoposide: Critical for EBV-infected pts, inhibits EBNA synthesis in EBV-infected cells

#### Genetic HLH: Bone marrow transplant

### More Information



The Histiocyte Society

#### www.histio.org

### References

#### Dr. Uthman

- Fisman, DN. Hemophagocytic syndromes and infection. *Emerging Infectious Diseases* (6), Nov-Dec 2000.
- Janka G & Uz Stadt. Familial and acquired hemophagocytic lymphohistiocytosis. *American Society of Hematology*, 2005.
- Robbins and Cotran. Pathologic Basis of Disease, 7<sup>th</sup> ed. 2005.
- Schaer DJ, Schleiffenbaum B et al. Soluble hemoglobinhaptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. *European Journal of Haematology* (74), 2005: 6-10.